Further studies are needed to better understand the specific pathway and mechanisms involved in the increase in ectopic ovarian cancer growth and protein levels of CB2 and TNFα following chronic administration of CB2 (JWH-133) agonist. This evidence concerns the gene TNF and ovarian cancer.